Social Media “Revolution” Expected In Adverse Events Signal Detection
This article was originally published in The Tan Sheet
Executive Summary
Technology is ready now, and the agency anticipates Twitter and Facebook will become part of the “key instruments” of pharmacovigilance in the next five years, says Henry Francis, CDER’s data mining chief.
You may also be interested in...
Social Media Guidance Gives Drug Firms A Pass On User Content
The draft guidance outlines substantial reporting requirements for websites that firms control and for content on third-party sites – as well as saying when FDA intends to use enforcement discretion.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.